{
    "clinical_study": {
        "@rank": "61990", 
        "arm_group": [
            {
                "arm_group_label": "Oestradiol and ultrashort GnRH agonist/antagonist protocol", 
                "arm_group_type": "Experimental", 
                "description": "Women will begin pretreatment with 4 mg/day of 17 \u03b2-estradiol before the combination of GnRH ultashort agonist and antagonist protocol"
            }, 
            {
                "arm_group_label": "GnRH agonist  or antagonist protocol.", 
                "arm_group_type": "Active Comparator", 
                "description": "Women will undergo either a conventional short or long GnRH agonist  or an antagonist protocol during COH for IVF"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the effect of oestradiol pre-treatment in a combined ultrashort flare GnRH\n      agonist /GnRH antagonist protocol"
        }, 
        "brief_title": "Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "detailed_description": {
            "textblock": "The combined ultrashort flare GnRH agonist /GnRH antagonist protocol during COH cycle\n      resulted in a significantly higher clinical pregnancy rate in patients with poor embryo\n      quality, with repeated IVF failures and in poor responders. This is a protocol combining the\n      effect of the microdose flare on endogenous FSH release with the benefit of an immediate LH\n      suppression of the GnRH antagonist.\n\n      A major disadvantage of the use of a GnRH antagonist protocol is the limitation for\n      programming cycles, as the drugs administration is started on day 2 of the menstrual cycle\n      and is strictly followed until the hCG criteria are met.\n\n      The purpose of the study is to perform oestradiol pre-treatment with the combined ultrashort\n      flare GnRH agonist /GnRH antagonist protocol aiming to\n\n        1. better programme an antagonist cycle and\n\n        2. improve the IVF outcome parameters, from the production of more follicles / oocytes up\n           to the rise in live birth rates."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with poor or no response in previous COH for IVF cycles\n\n          -  Patients with AMH < 1 and/or FSH >12\n\n          -  Poor quality of embryos in previous cycles\n\n          -  Age of patients up to 44 years\n\n        Exclusion Criteria:\n\n          -  Patients with normal ovarian reserve\n\n          -  Patients with sonographically detected hydrosalpinges\n\n          -  Presence of intramural fibroid distorting the endometrial cavity or submucous myoma\n             or Asherman's syndrome\n\n          -  Women with thrombofilia disorders"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "44 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798836", 
            "org_study_id": "030675"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oestradiol and ultrashort GnRH agonist/antagonist protocol", 
                "intervention_name": "Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "GnRH agonist  or antagonist protocol.", 
                "intervention_name": "GnRH agonist or antagonist protocol without oestradiol pre-treatment", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "Triptorelin", 
                "Deslorelin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "IVF/ICSI cycles, poor responders, ultrashort flare protocol, antagonist protocol", 
        "lastchanged_date": "November 29, 2013", 
        "location": {
            "contact": {
                "email": "gsalamalekis2006@gmail.com", 
                "last_name": "George Salamalekis, MD, PhD", 
                "phone": "693-664-7099", 
                "phone_ext": "0030"
            }, 
            "contact_backup": {
                "email": "harrysiri@yahoo.gr", 
                "last_name": "Charalampos Siristatidis, Assistant Professor", 
                "phone": "693-229-4994", 
                "phone_ext": "0030"
            }, 
            "facility": {
                "address": {
                    "city": "Athens", 
                    "country": "Greece", 
                    "state": "Attica", 
                    "zip": "12642"
                }, 
                "name": "Assisted Reproduction Unit, 3rd Department of Obstetrics and Gynecology. Attikon University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Maria Kreatsa, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Charalampos Chrelias, Assistant Prof. Ob/Gyn", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tereza Vrantza, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Paraskevi Vogiatzi, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eleni Alexiou, Chief midwife", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dimitrios Kassanos, Prof Ob/Gyn", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "2", 
        "official_title": "Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF", 
        "other_outcome": {
            "measure": "Positive Pregnancy Test", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "overall_contact": {
            "email": "gsalamalekis2006@gmail.com", 
            "last_name": "George Salamalekis, MD, PhD", 
            "phone": "693-664-7099", 
            "phone_ext": "0030"
        }, 
        "overall_contact_backup": {
            "email": "harrysiri@yahoo.gr", 
            "last_name": "Charalampos Siristatidis, Assistant Professor", 
            "phone": "693-229-4994", 
            "phone_ext": "0030"
        }, 
        "overall_official": [
            {
                "affiliation": "National and Kapodistrian University of Athens", 
                "last_name": "George Salamalekis, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National and Kapodistrian University of Athens", 
                "last_name": "Charalampos Siristatidis, Assistant Professor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ethics Committee: Greece", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Live birth rate", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Clinical pregnancy rate", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "reference": [
            {
                "PMID": "20537631", 
                "citation": "Griesinger G, Kolibianakis EM, Venetis C, Diedrich K, Tarlatzis B. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril. 2010 Nov;94(6):2382-4. doi: 10.1016/j.fertnstert.2010.04.025. Epub 2010 May 26."
            }, 
            {
                "PMID": "22656307", 
                "citation": "Bosch E. Can we skip weekends in GnRH antagonist cycles without compromising the final outcome? Fertil Steril. 2012 Jun;97(6):1299-300. doi: 10.1016/j.fertnstert.2012.04.024."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798836"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National and Kapodistrian University of Athens", 
            "investigator_full_name": "Siristatidis Charalampos, MD, PhD", 
            "investigator_title": "Assistant Professor in Obstetrics and Gynecology/Assisted Reproduction", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": [
            {
                "PMID": "18675974", 
                "citation": "Orvieto R, Nahum R, Rabinson J, Gemer O, Anteby EY, Meltcer S. Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist for patients with repeated IVF failures and poor embryo quality. Fertil Steril. 2009 Apr;91(4 Suppl):1398-400. doi: 10.1016/j.fertnstert.2008.04.064. Epub 2008 Aug 3."
            }, 
            {
                "PMID": "22464760", 
                "citation": "C\u00e9drin-Durnerin I, Guivarc'h-Lev\u00eaque A, Hugues JN; Groupe d'Etude en M\u00e9decine et Endocrinologie de la Reproduction. Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial. Fertil Steril. 2012 Jun;97(6):1359-64.e1. doi: 10.1016/j.fertnstert.2012.02.028. Epub 2012 Mar 28."
            }
        ], 
        "secondary_outcome": [
            {
                "measure": "Number of oocytes retrieved", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Top embryo quality at day 2", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Biochemical pregnancy", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Ectopic pregnancy", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Miscarriage rate", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "National and Kapodistrian University of Athens", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National and Kapodistrian University of Athens", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}